Core Viewpoint - Weisi Medical is a technology-driven medical device company focusing on rehabilitation solutions, experiencing significant growth in revenue and net profit in Q1 2025 due to market recovery and business expansion [1][2]. Group 1: Company Overview - Weisi Medical specializes in high-quality rehabilitation products and solutions, particularly in areas such as pelvic and postpartum rehabilitation, mental health rehabilitation, neurological rehabilitation, and pediatric rehabilitation [1]. - The company serves various medical institutions in China, including general hospitals, obstetrics and gynecology hospitals, psychiatric hospitals, children's hospitals, and rehabilitation hospitals [1]. Group 2: Financial Performance - In Q1 2025, the company's revenue increased by 9.4% year-on-year, reaching 96 million yuan, while the net profit attributable to shareholders grew by 52.71% to 33 million yuan [1]. Group 3: International Expansion - Weisi Medical participated in the Clinical TMS Society Annual Meeting in San Diego, showcasing its transcranial magnetic stimulation products, aiming to enhance its global influence in rehabilitation and mental health [2]. - The company is establishing an overseas marketing team in 2024, focusing on product registration, participation in international exhibitions, and developing partnerships, with initial sales efforts targeting Asia and South America [2]. Group 4: Product Development and Market Strategy - Weisi Medical has developed a comprehensive product matrix for rehabilitation robots, integrating various rehabilitation therapies to meet market demands [3]. - The company aims to provide intelligent, standardized, and assessable rehabilitation solutions, focusing on product quality, iterative upgrades, and cost optimization to strengthen its competitive position in the high-end rehabilitation market [3].

Group 1 - The stock of Weisi Medical (688580) has a comprehensive score of 56.49, indicating a strong performance [1] - The main cost analysis shows the following prices: current main cost at 45.93 CNY, 5-day main cost at 46.23 CNY, 20-day main cost at 45.31 CNY, and 60-day main cost at 43.88 CNY [1][2] - The stock has experienced one limit-up and no limit-down in the past year [1] Group 2 - The short-term resistance level is at 47.90 CNY, while the short-term support level is at 44.37 CNY [2] - As of July 3, 2025, the net outflow of main funds is 884.35 million CNY, accounting for 14% of the total transaction volume [2] - The financial data indicates earnings per share of 0.347 CNY, operating profit of 0.37 billion CNY, and a net profit of 33,220,075.05 CNY with a gross profit margin of 66.652% [3][2] Group 3 - The stock is associated with several sectors, including medical devices (0.43%), brain engineering (0.55%), medical device concepts (0.76%), and elderly care concepts (0.73%) [4]

Company Overview - Weisi Medical's closing price on July 1 was 47.9 yuan, reflecting a 3.03% increase, with a rolling PE ratio of 40.44, marking a 16-day low, and a total market capitalization of 4.587 billion yuan [1] - The company specializes in the research, production, and sales of medical devices, with key products including magnetic stimulation, electrical stimulation, electrophysiology, consumables and accessories, and laser radiofrequency [1] Financial Performance - In the first quarter of 2025, Weisi Medical reported revenue of 95.9127 million yuan, representing a year-on-year increase of 9.40%, and a net profit of 33.2201 million yuan, up 52.71%, with a gross profit margin of 66.65% [1] Shareholder Information - As of March 31, 2025, Weisi Medical had 5,933 shareholders, an increase of 637 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] Industry Comparison - The average PE ratio for the medical device industry is 51.70, with a median of 37.36, placing Weisi Medical at the 81st position within the industry [1][2] - The static PE ratio for Weisi Medical is 44.99, and the price-to-book ratio is 2.76 [2]

Meeting Overview - The fourth meeting of the fourth Supervisory Board of Nanjing Weisi Medical Technology Co., Ltd. was held on June 27, 2025, in a combined onsite and communication format [1][2] - All three supervisors attended the meeting, which complied with relevant laws and regulations [1][2] Resolutions Passed Adjustment of Stock Incentive Plan - The Supervisory Board approved the adjustment of the list of initial grant recipients and the number of shares for the 2025 Restricted Stock Incentive Plan, reducing the number of recipients from 74 to 71 and the number of shares from 904,000 to 872,000 [2][3] - The total number of restricted shares to be granted was adjusted from 1,000,000 to 968,000, with a reserve of 96,000 shares remaining unchanged [2][3] Granting of Restricted Stock - The Supervisory Board confirmed that the conditions for granting restricted stock to the incentive recipients had been met, approving the grant of 872,000 shares at a price of 22 yuan per share to 71 recipients on June 27, 2025 [4][5] Use of Own Funds for Project Financing - The Supervisory Board approved the use of the company's own funds to pay for personnel costs related to fundraising projects, with plans to replace these funds with equivalent amounts from raised funds later [5]

Core Points - The company, Nanjing Weisi Medical Technology Co., Ltd., is using its own funds to pay for investment projects and will replace these with raised funds later [1][10] - The total amount raised from the public offering was approximately RMB 1.15 billion, with a net amount of about RMB 1.06 billion after deducting issuance costs [1][10] - The company has adjusted the expected usable status dates for several projects, delaying them from September 2023 to December 2025 due to changes in internal and external environments [3][5][10] Fundraising Overview - The company issued 17,086,667 shares at a price of RMB 67.58 per share, with a face value of RMB 1.00 [1] - The total raised amount was RMB 1,154,716,955.86, with issuance costs of RMB 91,729,995.18 [1] Investment Project Status - The company has planned investments in several projects, including a research center and information technology projects, with total investment commitments adjusted to RMB 106,298.70 million [3][4] - The expected usable status for the "Research Center Construction Project" and "Information Technology Construction Project" has been extended to December 2025 [5][10] Reasons for Using Own Funds - The company needs to comply with regulations regarding salary payments, which require using basic or general deposit accounts rather than the fundraising account [7][8] - To enhance operational efficiency and reduce procurement costs, the company prefers to make bulk purchases using its own funds initially [8][9] Operational Process for Fund Replacement - The finance department will prepare detailed monthly reports on expenditures made with own funds, which will be reviewed and approved before transferring equivalent amounts from the fundraising account [9] - The company will maintain a ledger to track the replacement of funds, ensuring compliance with internal and external regulations [9][10] Impact on Daily Operations - The use of own funds for project payments and subsequent replacement with raised funds is expected to improve efficiency without affecting the normal implementation of investment projects [10] - The board and supervisory committee have approved the process, confirming that it does not harm the interests of the company or its shareholders [10][11]

Core Viewpoint - Nanjing Weisi Medical Technology Co., Ltd. has announced its 2025 restricted stock incentive plan, detailing the allocation of shares to various executives and key personnel, aimed at motivating and retaining talent within the company [1]. Summary by Relevant Sections Incentive Plan Allocation - The total number of restricted shares granted under the incentive plan is 96.80 million shares, which constitutes 20.00% of the company's total share capital [1]. - The allocation includes shares for the chairman, general manager, and core technical personnel, with specific amounts detailed for each individual [1]. Individual Allocations - Wang Zhiyu (Chairman and General Manager) is allocated 6.00 million shares, representing 6.20% of the total shares granted [1]. - Other key executives, such as Zhong Yiqun and Chen Lili (both Deputy General Managers), are allocated 3.50 million shares each, accounting for 3.62% of the total shares granted [1]. - The total allocation for other personnel deemed necessary for motivation is 54.86% of the total shares granted, with a reserve of 9.60 million shares [1]. Compliance and Disclosure - The company will disclose relevant information regarding the incentive plan in accordance with legal requirements after obtaining professional opinions from lawyers [2].

（1）最近 12 个月内被证券交易所认定为不适当人选的； （2）最近 12 个月内被中国证监会及其派出机构认定为不适当人选； （3）最近 12 个月内因重大违法违规行为被中国证监会及其派出机构行政处罚 或者采取市场禁入措施； （4）具有《公司法》规定的不得担任公司董事、高级管理人员情形的； （5）法律法规规定不得参与上市公司股权激励的； 南京伟思医疗科技股份有限公司监事会 关于 2025 年限制性股票激励计划首次授予激励对象名单 的核查意见（截至授予日） 南京伟思医疗科技股份有限公司（以下简称"公司"）监事会依据《中华人民 共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证 券法》"）、《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《上海证券交 易所科创板股票上市规则》（以下简称"《上市规则》"）、《科创板上市公司自律监管 指南第 4 号——股权激励信息披露》等相关法律、法规及规范性文件和《南京伟思 医疗科技股份有限公司章程》（以下简称"《公司章程》"）的有关规定，对公司 2025 年限制性股票激励计划（以下简称"本激励计划"）首次授予激励对象名单（截至 授予日）进 ...

证券代码：688580 证券简称：伟思医疗 公告编号：2025-024 南京伟思医疗科技股份有限公司 关于向激励对象首次授予限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 限制性股票首次授予日：2025 年 6 月 27 日 限制性股票首次授予数量：87.2 万股，占目前公司股本总额 9,577.1288 万股的 0.91% 股权激励方式：第二类限制性股票 《南京伟思医疗科技股份有限公司 2025 年限制性股票激励计划（草案）》 （以下简称"《激励计划》"）规定的授予条件已经成就，根据南京伟思医疗科 技股份有限公司（以下简称"公司"）2024 年年度股东大会授权，公司于 2025 年 6 月 27 日召开第四届董事会第四次会议、第四届监事会第四次会议，审议通 过了《关于向激励对象首次授予限制性股票的议案》，确定 2025 年 6 月 27 日为 公司 2025 年限制性股票激励计划（以下简称"本激励计划"）首次授予日，以 22 元/股的授予价格向 71 名激励对象授予 87.2 万股限制性 ...

证券代码：688580 证券简称：伟思医疗 公告编号：2025-023 南京伟思医疗科技股份有限公司 关于调整 2025 年限制性股票激励计划首次授予 激励对象名单及授予数量的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 同日，公司召开第四届监事会第三次会议，会议审议通过《关于<公司 2025 年限制性股票激励计划（草案）>及其摘要的议案》《关于<公司 2025 年限制性 股票激励计划实施考核管理办法>的议案》以及《关于核实<公司 2025 年限制性 股票激励计划首次授予激励对象名单>的议案》，公司监事会对本激励计划的相 关事项进行核实并出具了相关核查意见。 南京伟思医疗科技股份有限公司（以下简称"公司"）于 2025 年 6 月 27 日召开了第四届董事会第四次会议和第四届监事会第四次会议，审议通过了《关 于调整 2025 年限制性股票激励计划首次授予激励对象名单及授予数量的议案》。 现将有关事项说明如下： 一、本次股权激励计划已履行的相关审批程序 （一）2025 年 4 月 24 日，公司召开第四届董事会第三次 ...

注：1、公司全部在有效期内的股权激励计划所涉及的标的股票总数累计未超过公司股本总额的 20.00%。 上述任何一名激励对象通过全部在有效期内的股权激励计划获授的公司股票数量累计未超过公司股本总额 的 1.00%。 南京伟思医疗科技股份有限公司 2025 年限制性股票激励计划首次授予激励对象名单 （截至授予日） 一、 公司 2025 年限制性股票激励计划（以下简称"本激励计划"）的分配情况 | 姓名 | 国籍 | 职务 | 获授的限制性 股票数量（万 股） | 占本激励计 划拟授出权 益数量的比 | 占首次授予 日公司股本 总额的比例 | | --- | --- | --- | --- | --- | --- | | | | | | 例 | | | 王志愚 | 中国 | 董事长、总经理、核心技 术人员 | 6.00 | 6.20% | 0.06% | | 钟益群 | 中国 | 副总经理 | 3.50 | 3.62% | 0.04% | | 陈莉莉 | 中国 | 董事、副总经理、财务总 监 | 3.50 | 3.62% | 0.04% | | 张辉 | 中国 | 董事、副总经理 | 5.10 | 5.27% | ...